Wednesday, May 12, 2021 CCTG MYX1 (MCRN‐003): Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN‐003/MYX.1 single arm phase II trial The MCRN-003/MYX1 clinical trial was conducted collaboratively between the Canadian Myeloma Research Group (previously known as the Myeloma Canada Research Network) and the Canadian Cancer Trials Group. The trial evaluated a once-weekly carfilzomib dosing regimen, more convenient for patients and more cost-effective for the health care system. The primary endpoint was met with overall response rate over 80%. Dr. Christopher Venner from the Cross Cancer Institute in Edmonton was the Study Chair. Publication Venner CP, LeBlanc R, Sandhu I, White D, Belch AR, Reece DE, Chen C, Dolan S, Lalancette M, Louzada M, Kew A, McCurdy A, Monteith B, Reiman T, McDonald G, Sherry M, Gul E, Chen BE, Hay AE. Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN-003/MYX.1 single arm phase II trial. Am J Hematol 96: 552-60, 2021. https://onlinelibrary.wiley.com/doi/10.1002/ajh.26147
